

K981687

JUN 3 1998

**510 (k) SUMMARY
AS REQUIRED BY SECTION 807.92(C)**

Identification: QuickScreen™ Benzodiazepines Screening Test (9025/9026)

Description: Immunoassay for the qualitative detection of benzodiazepines in Urine

Name Of Manufacturer: Phamatech
9265 Activity Road #112
San Diego, California 92126, USA

Intended Use: The QuickScreen™ One Step Benzodiazepines Screening Test is a rapid, qualitative immunoassay for the detection of benzodiazepines compounds in urine. The cut-off concentration for this test is 200 ng/mL. This assay is intended for use in clinical toxicology laboratories, physicians' offices and drug of abuse clinics. Benzodiazepines form one of the largest classes of abused pharmaceuticals. These products are sedative and hypnotics, tranquilizers and anti-anxiety drugs which produce a calming effect, thus they are often prescribed as tranquilizers.

Technology: The QuickScreen™ Test, like many commercially available drug screening test kits, qualitatively measures the presence of benzodiazepines by visual color sandwich one step immunoassay technology. Examples of such predicate devices include the ABMC (Ancramdale, NY) and the Applied Biotech SureStep Test (San Diego, CA 92121). All of the above devices rely on the basic immunochemical sandwich assay principle of recognition and formation of specific antibody / benzodiazepines / antibody / complexes.

Performance: The product performance characteristics of the QuickScreen™ Benzodiazepines Screening Test were evaluated in a clinical sample correlation study and a blind labeled spiked study. The results of these studies demonstrate the Phamatech QuickScreen™ Test to be substantially equivalent to the reported performance characteristics of other commercially available tests for the qualitative detection of benzodiazepines in urine. Correlations studies, using clinical specimens, produced a >99% correlation when compared to the ABI SureStep (San Diego, CA 92121) and the EMIT II Test (San Jose, CA). A clinical laboratory study was also performed, the Phamatech QuickScreen™ exhibited excellent sensitivity (>99%), specificity (>99%), and accuracy (>99%) in the hands of professional users.

Conclusion: For the reasons mentioned above, it may be concluded that the Phamatech QuickScreen™ Benzodiazepines Screening Test is substantially equivalent to a variety of benzodiazepines detection tests currently in commercial distribution.

RECEIVED
13 MAY 98 10 42
FDA/CDRH/ODE/DNC



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
2098 Gaither Road
Rockville MD 20850

JUN 3 1998

Carl Mongiovi
Director of Operations
Phamatech
9265 Activity Road #112
San Diego, California 92126

Re: K981687
QuickScreen™ Benzodiazepines Screening Test (Models
9025, 9026) QuickScreen™ Pro Multi Drug Screening Test
(Model 9151)
Regulatory Class: II
Product Code: JXM
Dated: May 8, 1998
Received: May 13, 1998

Dear Mr. Mongiovi:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

Page 2

Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770) 488-7655.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "<http://www.fda.gov/cdrh/dsmamain.html>".

Sincerely yours,

Steven Gutman

Steven I. Gutman, M.D., M.B.A.
Director
Division of Clinical
Laboratory Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

